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Randomized controlled trials of pharmaceutical care: A systematic review 1 
Abstract 2 
Objective 3 
To review the effects of pharmaceutical care on hospitalizations, mortality and clinical outcomes in 4 
patients. 5 
Methods 6 
Systematic searches were conducted in MEDLINE, EMBASE and International Pharmaceutical Abstracts 7 
(IPA) databases to identify studies that were published between 2004 and January 2017. Studies 8 
included in this review were randomized controlled trials (RCTs) that spanned across both community and 9 
hospital settings. Using strict inclusion/exclusion criteria studies were included if they reported level 1 or 2 10 
outcomes in the hierarchy of outcome measure i.e. clinical and surrogate outcomes (e.g. blood pressure 11 
(BP) control, blood glucose level, cholesterol BMI). Each study was assessed for quality using the Jadad 12 
scoring system. 13 
Results 14 
Fifty-four RCTs were included in the present review. Forty-six of these studies ranked high quality 15 
according to the Jadad scoring system. Studies were categorized into their general condition groups. 16 
Interventions in patients with diabetes, depression, respiratory disorders, cardiovascular disorders, 17 
epilepsy, osteoporosis, and interventions in older adults were identified. In the majority of studies 18 
pharmaceutical care was found to lead to significant improvements in clinical outcomes and/or 19 
hospitalizations  when compared to the non-intervention group. Some conditions had a large number of 20 
RCTs, for example for cardiovascular conditions and in diabetes. Statistically significant improvements 21 
were seen in the majority of the studies included for both of these conditions, with studies indicating 22 
positive clinical outcomes and/or hospitalizations rates. Within the cardiovascular condition, a subset of 23 
studies, focusing on cardiac heart failure and coronary heart disease, had more mixed results. In other 24 
conditions the number of RCTs conducted was small and the evidence did not show improvements after 25 
pharmaceutical care, i.e. in depression, osteoporosis, and epilepsy. The majority of interventions were 26 
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face to face interactions with patients, whilst a smaller number were conducted via the telephone and one 27 
via a web-based system. Patient education was a key component of most interventions, either verbal 28 
and/or written.  Longitudinal data, post intervention cessation, was not collected in the majority of cases. 29 
Conclusions 30 
RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term 31 
outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other 32 
conditions such as depression are less well researched. Future research should attempt to evaluate the 33 
conditions where there is a lack of data, whether the positive effects of pharmaceutical care persist in 34 
patient populations after the interventions cease and what the long-term clinical outcomes would be of 35 
continued pharmaceutical care. 36 
  37 
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Introduction  38 
Worldwide, the demands on primary health care services are growing,  mainly due to an ageing 39 
population (1). The consequence of this is an increased strain on the primary health care workforce (3-6) 40 
and as a result, primary health care systems have evolved to encompass new services. In some 41 
countries, this has led to extended roles for community pharmacists (7, 8). The pharmacy profession is 42 
evolving worldwide, moving from the traditional role of the technical dispenser to be more patient-focused 43 
(9). The concept of pharmaceutical care was first conceived by Hepler and Strand and is defined as the 44 
responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a 45 
patient’s quality of life (10). According to the concept of pharmaceutical care, the patient care process is 46 
comprised of the establishment of a therapeutic relationship, assessment of medication related problems, 47 
development of a care plan, evaluation and continuous follow-up (11). Pharmacists are responsible for 48 
the quality and effectiveness of pharmaceutical care for the benefit of patients to improve their health care 49 
outcomes (12).  50 
Since its conception, various terms have been used to describe pharmaceutical care including medication 51 
review, medication management, clinical pharmacy services and cognitive services and all of these are 52 
defined by similar practices (13). According to some authors, pharmaceutical care is closely related to 53 
medicines management but includes the patient’s perspective and pharmacists societal perspective (14). 54 
Pharmacists counsel patients with a focus on educating health management or drug related-problems 55 
(identification, resolution or prevention), they develop a care-plan for the individual patient and follow-up 56 
the pharmacotherapy (15).  57 
Studies investigating the effects of  pharmaceutical care on short and long term patient outcomes have 58 
been increasing over the past two decades; however there are mixed reports of whether the 59 
pharmaceutical care interventions are effective or not, with the intervention not always showing significant 60 
differences (16-18).  Systematic reviews often focus on specific conditions for example, reviews have 61 
been conducted in patients with  hypertension (19, 20) and in chronic kidney disease (21) and others 62 
have looked at pharmaceutical care in specific settings for example, in community pharmacy (22).   63 
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A previous systematic review of studies published between 1990 and 2003 was published in 2005. This 64 
review evaluated the effectiveness of pharmaceutical care across all conditions and concluded that the 65 
pharmaceutical care is effective in improving surrogate outcomes but less conclusive in other outcomes 66 
(23). Evidence of the effect of pharmaceutical care is constantly growing and regular systematic 67 
evaluation is important and relevant to healthcare. This current study included randomized controlled 68 
trials (RCTs) published since 2004 across all conditions, to evaluate the evidence of whether 69 
pharmaceutical care is effective for patients.  The objective of this systematic review was to examine the 70 
effects of pharmaceutical care using patient outcomes (i.e. clinical and surrogate outcomes) in both the 71 
hospital and community setting.. 72 
  73 
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Methods 74 
Search strategy 75 
The PRISMA guidelines for conducting the systematic review were followed. A systematic search of the 76 
literature was conducted to identify RCTs published in English language between 2004 and January 2017 77 
by using the electronic databases: Medline (Ovid SP), International Pharmaceutical Abstracts (IPA) and 78 
Embase. Our search included both mapped and unmapped terms, which are illustrated in figure 1. In 79 
addition, the following text words and MeSH/EMTREE terms were used to see if there were any 80 
additional relevant papers: The databases were searched for the following key terms in combination 81 
where appropriate: (“Pharmaceutical services”), (“Pharmaceutical care”),  (“Medicine management”), 82 
(“Medicine therapy assessment”), (“Medicine therapy management”), (“Drug therapy management”) 83 
(“Pharmacy services”) (“Medication review”), (“Comprehensive medication review”), (“drug utilization 84 
management”), (“Drug therapy services”), (“Pharmacist intervention”) and (“Patient centered care” and 85 
Medicines” or “Drug” or “Pharmac*”). We combined these keywords with the filter “Randomized controlled 86 
trial”, if the filter was not available on that data base then a keyword was used and the study’s 87 
methodology was evaluated to ensure only randomized controlled trials were included. See Figure 1 for 88 
Prisma flow diagram.  89 
Inclusion/exclusion criteria 90 
The inclusion and exclusion criteria are detailed in Table 1. Studies were included in this review if they 91 
referred to a pharmaceutical care intervention in adult patients and the intervention included the role/input 92 
of a pharmacist. All healthcare settings were included i.e. both hospital and community based 93 
interventions. Studies were excluded if they were not written in English, did not have a full text article 94 
available, or if they were reviews, commentaries or letters to the editor. Studies published before 2004 95 
were also excluded. Our review’s aim was to evaluate RCTs that assessed pharmaceutical care, so all 96 
studies were excluded if they were not RCTs, including cluster RCTs and any pilot data. RCTs were only 97 
included in this review if they measured patient outcomes that were either level 1 or 2 in the hierarchy of 98 
outcome measures (Table 2.) 99 
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Jadad scores of methodology quality  100 
A quality assessment was completed for each randomized controlled trial using the Jadad checklist (24). 101 
A Jadad score of equal to or greater than 3 is indicative of a high-quality study (19). The 102 
assessment criteria for the Jadad scoring are detailed in Figure 2. The Jadad score has been 103 
used as a tool in previous literature evaluating RCTs (19, 25).  104 
Table 1. Study inclusion and exclusion criteria 105 
No Category Inclusion criteria 
1 Language of 
publication 
English 
2 Year of publication 2004-January 2017 
3 Publication type  Full text RCTs discussing effect of pharmacy (pharmacists) services on 
patients health care outcomes. 
4 Outcomes measures RCTs measuring patient’s outcomes i.e. clinical and surrogate outcomes 
(e.g. blood pressure (BP) control, blood glucose level, cholesterol BMI). 
Outcome measures must fall in level one or two of the hierarchy of 
outcome measures, described in table 2. 
5 Methodology Studies included, must demonstrate pharmacist’s induced interventions by 
patient’s homes visits or in any of healthcare setting including primary, 
secondary or tertiary heath care settings or nursing home residents.  
6 Pharmacists role Pharmacist must play the significant or integral role, where 
multidisciplinary models were presented.                                             
7 Patients  Adult patients only. 
No 
 Exclusion criteria  
1 Language of 
publication 
Published in other than English  
2 Year of publication Published before 2004 
3 Publication type Abstracts, reports, commentaries, editorials, book chapters, reviews, 
secondary research (systematic reviews, meta-analysis)  
4 Outcomes measures RCTs with only patient’s satisfaction as an outcome measure  
5 Methodology RCTs published as protocol of study 
6 Methodology Pilot studies were excluded 
7 Methodology Cluster RCTs 
  106 
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Results 107 
Studies selection  108 
The literature search identified 669 titles/abstracts that contained the aforementioned key terms. The titles 109 
and abstracts of all selected articles were reviewed for relevance. The search results were further 110 
checked and reviewed by a second author. In case of any doubt regarding papers, the full text article was 111 
reviewed for relevance. Inclusion criteria were formulated in relation to the research aims.  112 
A total of 218 studies were screened and assessed for eligibility.  Of these 54 RCTs fulfilled the inclusion 113 
criteria. The flow diagram (Figure 1) details the process in which the studies were identified, screened 114 
and included in this review. The inclusion and exclusion criteria of study are summarized in Table 1. 115 
Data extraction and analysis 116 
Two researchers (LC, RK) independently extracted study characteristics, using an extraction table. One 117 
researcher (LC) compared all extracted data and discussed discrepancies with other researchers (ZB) 118 
when necessary. The data were then grouped based on the condition that they aligned with and a 119 
summary of the data extracted from the studies is presented in Tables 3-8. This includes the country of 120 
origin, patient group included, follow-up period, number of patients in each arm, setting, description of the 121 
intervention outcomes measured, level of hierarchy of outcome measured and a summary of results.  122 
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 123 
 124 
  125 
(“Pharmaceutical services”) or (“Pharmaceutical care”) or 
(“Medicine management”) or (“Medicine therapy 
assessment”) or (“Medicine therapy management”) or 
(“Drug therapy management”) or (“Pharmacy services”)  or 
(“Medication review”) or  (“Comprehensive medication 
review”) or  (“drug utilization management”) or (“Drug 
therapy services”) or (“Pharmacist intervention”)  or 
(“Patient centered care” ) 
(“Medicines”) or (“Drug”) or 
(“Pharmaceutical”) or  
(“Pharmac*”) 
Medline 
(n = 339) 
Embase 
(n = 441) 
 
International Pharmaceutical 
Abstracts (IPA)  
(n = 3914) 
 
+ 
Records after duplicates removed (n =669) 
 
Full-text articles assessed
for eligibility 
(n= 48) 
Studies included, see table 1 for 
inclusion criteria
(n = 54) 
 
Studies included in
review 
(n = 54 papers) 
 
Records excluded, see table 1 
for exclusion criteria  
(n =451) 
 
Records screened: 
 
Removed based on title / abstract  
n =218 
 
Records excluded, see table 1 
for exclusion criteria  
(n =170) 
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Figure 1: The process of identification, screening and inclusion of papers for this review. 
Limit: English language; 2004- January 2017; Limit RCT 
 
Full text articles found from 
references and hand searching 
(n=6) 
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Table 2. Hierarchy of outcome measures (Adapted from AHRQ, 2001)(26) 126 
Level  Description 
1 Clinical outcomes - morbidity, mortality, hospitalizations  
2 Surrogate outcomes - observed errors, intermediate outcomes (eg, laboratory 
results) with well-established connections to the clinical outcomes of interest 
(usually adverse events). 
3 Other measurable variables with an indirect or unestablished connection to the 
target safety outcome (e.g., pre-test/post-test after an educational intervention, 
operator self-reports in different experimental situations) 
4 No outcomes relevant to decreasing medical errors and/or adverse events (e.g., 
study with patient satisfaction as only measured outcome; article describes an 
approach to detecting errors but reports no measured outcomes) 
 127 
Figure 2. Quality assessment of included randomized controlled trials through the Jadad checklist (24) 128 
 
Assessment questions to ascertain Jadad score 
 
1. Study randomized? 
2. Randomization was described and appropriate? 
3. Study double blind? 
4. Double blinding was described and appropriate? 
5. Withdrawals and dropouts were described? 
 
Totals added to produce Jadad score (max 5) 
  129 
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Studies Characteristics 130 
The included studies (n=54) were performed over a number of countries including Australia (n=2), 131 
Belgium (n=2), Brazil (n=6), Canada (n=2), Chile (n=2), China (n=4), Colombia (n=1), Denmark (n=1), 132 
Hong Kong (n=2), Iraq (n=1), Jordan (n=5), Malaysia (n=2), Norway (n=1), Portugal (n=1), Spain (n=2), 133 
Sudan (n=1), Sweden (n=1), Taiwan (n=1) Tasmania (n=1), Thailand (n=1), the United Kingdom (UK) 134 
(n=4), United States of America (USA) (n=8) and United Arab Emirates (UAE) (n=3). All of the studies 135 
were conducted within the specified country, i.e. not over more than one country. 136 
The targeted population included patients with specific condition(s) or those on a specific therapy. The 137 
RCTs can be further categorized into the following categories based on therapeutic condition; 138 
cardiovascular (CV) conditions (n=24), diabetes (n=15), depression (n=2), older adults (n=6), respiratory 139 
(n=3) conditions or other studies (those on multiple medicines, osteoporosis and epilepsy) (4).  140 
The RCTs included in the review involved follow up period from 30 days to 36 months. The most common 141 
follow-up periods were as follows: 19 RCTs included interventions with a follow up period of 6 months, 142 
seventeen RCTs with 12 months, and six studies with 3 months follow-up. Follow-up was conducted in 143 
some studies by face-to-face meetings; others used web-based communications and telephone contact. 144 
Jadad scores of methodology quality  145 
Randomized controlled trials with a Jadad score equal to or greater than 3 are indicative of a high-quality 146 
study (19). In this review the Jadad scores were recorded in the data extraction tables. Forty-six of the 147 
studies in this review ranked 3 or above in the Jadad scale. One study ranked a 5 score. The main 148 
reason for loss of points on this score chart was nature of the study design i.e. not being double-blinded. 149 
Interventions 150 
The majority of the pharmaceutical care interventions assessed by RCTs in this review included 151 
educational interventions for patients. Educational interventions involved the verbal or written information 152 
to improve the knowledge and awareness of patients regarding their diseases. Behavioral interventions 153 
included changes in patient compliance by modifying their attitude to medication adherence to drug 154 
therapy.  155 
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Some RCTs used one of the above interventions as single and others applied in combination 156 
(multifaceted). The interventions were applied and their effects on patient’s health care outcomes 157 
including clinical outcomes (morbidity, mortality, and hospitalizations) and surrogate clinical outcomes 158 
(laboratory results) were measured. Table 3-8 summarizes important characteristics of the studies 159 
included in the review. 160 
Some studies used the Dader method of pharmaceutical care. This method includes “patient education 161 
about CV drugs, completion of a drug therapy profile and/ or drug history, assessment of drug 162 
compliance, patient counseling about lifestyle modifications, pharmacist-performed interventions not 163 
related to changes in drug therapy, and pharmacist-delivered treatment recommendations to physicians” 164 
(27). 165 
In many RCTs in this review, follow-up took place on a frequent regular basis through the study, whereby 166 
a pharmacist contacted the patient either via home visits, appointments or via the telephone.  167 
Outcomes  168 
This review sought to identify RCTs that had evaluated pharmaceutical care interventions in patients 169 
across all conditions. The outcomes that we were interested in were those that are described in table 2, 170 
meeting criteria one or two, i.e. hospitalizations or unintended use of medical care, mortality and clinical 171 
outcomes that have been shown to be directly related to the progression/severity of the condition. In 172 
some instances these studies also reported other measures, which have been included in the table for 173 
completeness but are not discussed in the results section. Criteria that each study reported are recorded 174 
in the level of outcome measure in the tables 3-8. 175 
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Table 3. RCTs evaluating pharmaceutical care in cardiovascular disorders (n=24) 176 
Reference  and 
country 
Jadad 
score 
Sample size 
(completed  
follow up) 
Study 
population 
Follow up 
period   
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcome Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
AMARILES et al. 
2012 (27) 
Spain 
3 714 patients 
(Control=35
8, 
Intervention
= 356) 
Aged between 25-
74 years 
Prescribed with at 
least one drug 
indicated for CVD 
or CV risk factors  
8 months Multicenter 
community 
pharmacies 
Comparison between control 
and intervention group on the 
bases of Dader method for 
pharmaceutical care provided to 
intervention group only. Patients 
had at least 5 appointments with 
the pharmacist throughout the 
time frame.  
 BP,TC & BP/TC L2 Statistical significant 
difference in all 
measures. 
BELL et al. 2016 
(28) USA 
3 851 patients 
(Controls = 
428; 
Intervention 
= 423) 
Adults 
hospitalized with 
a diagnosis of 
acute coronary 
syndrome and/or 
acute 
decompensated 
heart failure 
30 days Vanderbilt 
University 
Hospital 
(VUH) and 
Brigham and 
Women’s 
Hospital 
(BWH) 
Reconciliation of preadmission 
medications and discharge 
medications with the patient and 
reported to the medical team. 
Provided tailored counselling to 
patient. 
At discharge, the pharmacist 
provided additional counselling, 
a written information chart and 
showed patient how to use 
pillbox. 
After hospital discharge, study 
coordinators contacted the 
patients for follow-up. 
Time to first unplanned 
health care utilization. 
L1 Statistically significant 
difference in 
unplanned 
health care utilization 
among patients with 
inadequate 
health literacy 
Community 
Pharmacy 
Medicines 
Management 
Project 
Evaluation 
Team. 2007 (29) 
UK 
2 1493  
patients 
(Control= 
513, 
Intervention
= 980), 62 
pharmacists 
& 164 
general 
physicians. 
Aged > 17 years, 
registered with 
general practices 
& with Coronary 
heart disease  
12 months 9 study sites 
from primacy 
care 
organizations 
(community 
pharmacies 
with private 
consultation 
areas) 
Consultation included: 
assessment of therapy and 
medicines. Compliance, lifestyle 
& social support 
Primary outcomes:  
Proportion of pts receiving 
secondary prevention 
treatment for CHD, Health 
status (SF36, Euro QOL), 
health economic analysis. 
Secondary outcomes: 
5-yr risk of CV death, 
patient satisfaction & 
compliance. 
L2&3 No statistical 
significant difference. 
 
Statistical significant 
difference in NHS-
related cost. 
 
No significant 
difference in 5-yr risk 
but significant 
difference in 
satisfaction 
DE CASTRO et 
al. 2006 (30) 
Brazil 
4 64 patients 
(Control=34, 
Intervention
=30) 
Aged ≥ 18 years , 
having 
uncontrolled 
hypertension,  
receiving 
treatment for 
hypertension  
6 months Hospital de 
Clininicas de 
Porto Alegre 
Pharmaceutical care provided by 
9 trained pharmacists. 
Patients were also provided 
printed educational material. 
Control group patients were 
allocated to sham intervention. 
5 meetings were conducted over 
the time period with a 
pharmacist.  
The intervention was compared 
BP measured  by ABP 
monitoring 
 
Medication adherence 
 
DRP identification 
L2&3 Decrease in BP in 
intervention group. 
 
No significant 
difference in 
adherence  
 
31 out of 37 DRP in 
intervention group 
were provided specific 
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to sham condition. intervention 
FIRMINO et al. 
2015 (31, 32) 
Brazil 
3 36 patients 
(Controls = 
15; 
Intervention 
= 21) 
Patients  
with systemic 
hypertension who 
had uncontrolled 
blood pressure 
(BP)  and/or 
presence of 
cardiovascular 
risk factors, or 
difficult control 
and 
adherence 
problems to the 
treatment 
9 months  The pharmacy 
unit of Dr. 
Anastacio 
Magalhães 
Primary Health 
Care 
Intervention group received 
orientation about taking 
medicines, actions aiming to 
prevent/solve medicine 
interactions and adverse 
effects and non-pharmacological 
interventions for 9 months 
Glucose, total cholesterol 
and its fractions,  
triglyceride and BP 
measurements to 
calculate cardiovascular 
risk rate and Framingham 
score. 
L2 Significant difference 
in cardiovascular risk 
rate and Framingham 
score. 
GARCIA et al. 
2015 (33) 
Norway 
3 94 patients 
(Control = 
46; 
intervention 
48) 
Only patients 
with established 
CHD were eligible 
for inclusion. 
12 months University 
Hospital of 
North Norway 
Intervention group follow-up 
from the clinical pharmacist at 
three points of time; after 
discharge at the ward and at  3 
months and 12 months at the 
hospital pharmacy . 
 
Primary outcomes: 
adherence to clinical 
guideline 
recommendations 
concerning prescription, 
therapy goal achievement 
and lifestyle education. 
Secondary outcomes: 
changes in the biomedical 
risk factors cholesterol, BP 
and blood glucose. 
L2&3 Overall adherence  
was significantly 
higher in the 
intervention group. 
No other significant 
differences. 
GREEN et al. 
2008 (34) USA 
5 730 patients 
(Control = 
247; Group 
2 =  246; 
Group 3 = 
237) 
Patients with a 
hypertension 
diagnosis and 
taking 
antihypertensive 
medication. 
12 months  10 medical 
centers 
Two intervention groups. Group 
2: Home BP monitoring and 
secure patient Web site training 
only, or group 3: home BP 
monitoring and secure patient 
Web site training plus 
pharmacist care management 
delivered through Web 
communications. 
Percentage of patients 
with controlled and 
changes in systolic and 
diastolic BP 
L2 Significant differences 
in the pharmacist 
group for all 
measures.  
HAMMAD et al 
2011 (35) 
Jordan 
3 65 patients 
(Control = 
22; 
Intervention 
43) 
Patients with 
metabolic 
syndrome as 
defined by the 
NCEP/ATP III 
criteria. 
6 months Outpatient 
clinics 
Monthly meetings with the 
pharmacist. Pharmacists 
provided medication counselling, 
answered questions, offered 
instructions on self-monitoring 
BP and advised patients on 
healthy lifestyle choices. 
Educational materials were also 
distributed to patients in the 
intervention group, including 
brochures 
Metabolic syndrome 
status, changes in mean 
values for each metabolic 
syndrome component 
(waist circumference, 
triglycerides, HDL-C, 
fasting blood  glucose, and 
systolic and diastolic BP) 
and for body weight. 
L2 Statistical significance 
in mean TG, SBP and 
DBP measures.  
 
HOLLAND et al 
2007 (36) UK 
3 291 patients 
(Control = 
143; 
Intervention 
Patients with 
heart failure from 
three hospitals 
who had been 
6 months  Outpatient 
(Discharged 
from hospital 
emergency). 
Two home visits by a community 
pharmacist within two and eight 
weeks of discharge. 
Pharmacists reviewed drugs and 
Primary outcome: total 
hospital readmissions at 
six months.  
Secondary outcomes: 
L1&2 No significant 
difference in any 
measure  
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= 148 ) admitted to the 
emergency room 
(on discharge). 
gave education on the condition, 
symptom self-management and 
lifestyle advice and advised use 
of symptom diary. 
mortality and QOL 
LALONDE et al. 
2008 (37) 
Canada 
3 150 patients 
(Control = 
122; 
Intervention 
= 128 ) 
Patients 
prescribed 
warfarin that had 
no anticoagulation 
treatment in the 
past 24 months. 
3 months Community 
hospital  
Follow up by pharmacist-
managed anticoagulation 
services 
INR control, incidence of 
complications, HRQOL, 
use of health care 
services, and direct 
incremental cost of PMAS  
L1, 2 &3 No significant 
differences.  
 
LEE et al 2006 
(38) USA 
3 159 patients 
(Control = 
76; 
Intervention 
= 83 ) 
Aged >75 who 
were taking 4 or 
more medications  
6 months  Walter Reed 
Army Medical 
Center’s 
Armed Forces 
Retirement 
Home 
Patients in the intervention 
group met with pharmacists 
every 2 months, and were 
provided blister- packed 
medications and also continued 
medication education as 
needed. 
Primary outcome: 
proportion of pills taken vs 
baseline; secondary end 
points: changes in BP and 
LDL-C 
L2&3 Significant differences 
in adherence and 
systolic BP 
LEE et al 2009 
(39) Hong Kong 
3 118 patients 
(Control = 
60; 
Intervention 
= 58) 
Patients taking 
one or more lipid-
modifying 
agents for 
dyslipidemia; who 
had a baseline 
lipid profile  
not reaching 
targeted LDL-C 
goal 
Unclear; 
within 16 
weeks 
Outpatient 
clinics 
Patients in the intervention 
group were counselled and 
provided with written 
information. A phone follow-up 
was done every 4 weeks 
between the initial counselling 
and the next follow-up interview 
for each patient. 
LDL-C, HDL-C, TC and 
TG 
L2 Significant differences 
in the pharmacist 
group for all 
measures. 
MA et al 2010 
(40) USA 
3 554 patients 
(Control = 
261; 
Intervention 
= 293 ) 
Known 
coronary heart 
disease 
12 months  Cardiac 
catheterization 
laboratories at 
hospital. 
Participants in the PI condition 
received 5 pharmacist-delivered 
telephone counselling calls post-
hospital discharge.  
Also received an education 
packet, dietary goal booklet, 
medicine card and pillbox. 
Percentage of patients 
with a serum LDL-C level 
<100 mg/dl 
L2 No significant 
difference 
MORGADO et al 
2011 (41) 
Portugal 
3 197 patients 
(Control = 
99; 
Intervention 
= 98) 
Hypertensive 
patients  
9 months  Outpatient 
clinic in a 
teaching 
hospital 
The pharmacist interventions, 
aimed to increase medication 
adherence and BP control, 
involved educational 
interventions and counselling 
tips directed to the patient and 
involved a quarterly follow up for 
9 months  
Systolic BP, diastolic BP  
and BP control, and 
adherence 
L2 Significantly lower 
sBP, dBP, BP control 
and adherence  
MURRAY et al 
2007 (42) USA 
3 270 patients 
(Control = 
164; 
Intervention 
= 106) 
Low-income 
patients with heart 
failure 
9 months  University-
affiliated, 
inner-city, 
ambulatory 
care practice. 
When medications were 
dispensed, the pharmacist 
provided patient-centered verbal 
instructions and written materials 
about the medications written for 
those with low health literacy.  
Monthly calls to assess QOL 
and interviews at 3, 6, 9, and 12 
Primary outcomes: 
adherence and 
exacerbations requiring 
emergency department 
care or hospital admission. 
Secondary outcomes: 
included health-related 
quality of life, patient 
L1,2&3 Reductions seen but 3 
months post 
intervention dissipated  
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months. satisfaction with pharmacy 
services, and total direct 
costs. 
PAULOS et al 
2005 (43) Chile 
1 42 patients 
(Control = 
19; 
Intervention 
= 23) 
Those who 
purchased their 
medication or 
requested blood 
cholesterol or 
triglyceride 
analysis 
16 weeks Outpatient 
pharmacy  
Intervention included obtaining 
total blood cholesterol 
and triglyceride levels as well as 
patient education. Patients had 
five follow-up appointments 
 
Total blood cholesterol 
level, triglyceride level, 
and body mass index 
(BMI) and adherence & 
QOL. 
L2&3 Total cholesterol and 
TG significant 
improvements. 
PETERSON et 
al 2004 (44) 
Tasmania 
3 81 patients 
(Control = 
42; 
Intervention 
= 39) 
Patients with 
dyslipidaemia. 
6 months  Royal Hobart 
Hospital 
Intervention group were visited 
at home monthly by a 
pharmacist, who provided 
education, assessed patients for 
drug-related problems, and 
measured total blood cholesterol 
levels using point-of-care 
testing. 
Blood cholesterol levels L2 Significant 
improvements in the 
cholesterol levels in 
the intervention group 
PLASTER et al. 
2012 (45) Brazil 
2 74 patients 
(Control=36, 
Intervention
= 38) 
At least 3 of 
conditions 
recommended by 
the NCEP-ATP III 
& BGMS for the 
diagnosis of 
metabolic 
syndrome. 
6 months Out patients of 
a primary 
health care 
unit (CHC)  
Patients participated in PC 
program  according to the Dader 
methodology 
Mean Arterial Pressure 
(MAP), NOM,   adherence 
level (Morisky test), CVD 
risk. 
L2&3 Statistical significant 
improvements in CVD 
risk 
QUDAH et al 
2016 (46) 
Jordan 
3 52 patients 
(Control = 
25; 
Intervention 
= 27) 
Hypertensive 
patients receiving 
hemodialysis 
3 months Outpatient 
hemodialysis 
units of Jordan 
University 
Hospital and 
Isra’a Hospital 
Doctor-pharmacist collaboration 
in addition upon enrolment, 
educational materials were 
distributed and discussed with 
patients in the intervention arm. 
Monthly follow-up by pharmacist 
for DRP and education. 
% of patients achieving BP 
below or equal 135/85 
mmHg. Secondary 
measures 
that were assessed 
include absolute reduction 
in peridialysis BP, 
interdialytic weight gain, 
adherence to medications 
and dialysis sessions 
L2&3 Statistical significance 
in the % of patients 
reaching BP target 
and weekly home 
systolic BP 
measurements  
SADIK et al. 
2005 (47) UAE 
3 208 patients 
(Control= 
104, 
Intervention
= 104) 
Diagnosed with 
heart failure & 
cognitive status 
12 months Al-Ain Hospital  Patients were education on HF, 
prescribed medications & 
management of HF symptoms, 
self- monitoring program. Printed 
booklet was also provided. 
2-min walk test, forced 
vital capacity, SBP, DBP & 
pulse, QOL questionnaire 
(MLHFQ, SF36). 
Patient assessment 
questionnaires for 
medication knowledge & s 
elf- reported compliance  
L1,2&3 Statistical significant 
difference 
SOOKANEKNU
N et al 2004  
(48) Thailand 
3 235 patients 
(Control = 
117; 
Intervention 
= 118) 
Hypertensive 
patients 
6 months  Mahasarakha
m University 
pharmacy and 
2 primary care 
units 
The patients in the intervention 
group had monthly consultations 
The research pharmacist 
assessed the patient’s 
understanding of medications, 
counselled on the use of their 
BPs, tablet counts, 
lifestyle modifications 
L2&3 Significant reductions 
in the systolic and 
diastolic BP and 
Patients whose BP 
stabilized and in 
adherence  
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medications, assessed 
adherence and lifestyle habits, 
reviewed for adverse events due 
to drug-related problems, and 
discussed factors associated 
with uncontrolled BP and 
disease state control and made 
recommendations to the 
prescriber. Educational leaflets 
were also given 
VILLA et al 2009 
(49) Chile 
2 142 patients 
(Control = 
57; 
Intervention 
= 85 ) 
Diagnosed with 
dyslipidaemia 
32 weeks  Primary 
Health Care 
centers 
Intervention group patients 
received care twice a month by 
pharmacists and drug related 
problems were identified.  
 
Knowledge about their 
illness and medications, 
adherence to drug 
therapy, and quality of life. 
In addition to HDL-c, LDL-
c, TG and TC 
L2&3 Significant 
improvements in all 
measures apart from 
HDL-c 
WANG et al 
2011 (50) China 
3 59 patients 
(Control = 
30; 
Intervention 
= 29) 
Hypertensive 
patients  
12 months Outpatient 
receiving 
antihypertensi
ve drugs 
Intervention group received 
education and met with clinical 
pharmacists every 2 months. 
Any drug related problems 
identified were reported to the 
physician.  
SBP and DBP plus 
adherence 
L2&3 Significant differences 
in SBP and DBP 
ZHAO et al. 
2012  (51) China 
3 Control=129
, 
Intervention
=129 
Aged b/w 21-85 
years, diagnosed 
with hypertension,  
6 months Xijing Hospital  Recommendations to physicians 
and educational and counselling 
directly to patients. 
Follow-up at 6 months at clinic. 
SBP, DBP, BP control and 
medication adherence 
L2 &3 
 
 
Significant difference 
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Table 4. RCTs evaluating pharmaceutical care in diabetes mellitus (n=15) 179 
Reference  and 
country 
Jadad 
score 
Sample size  Study population Follow up 
period  
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcomes Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
AL MAZROUI et 
al. 2009 (52) 
UAE 
3 234 patients 
(control=117
, 
intervention
= 117) 
Diagnosed with type 
2 diabetes mellitus, 
oral hypoglycemic 
therapy. 
 
12 months Zayed Military 
hospital 
The intervention group received 
patient education about illness & 
medication, provided with 
leaflets, behavioural 
modifications from a pharmacist. 
The intervention group had 4 
monthly appointments at 
hospital 
BMI, fasting blood glucose 
level, HbA1c, BP, serum 
TC, LDL-C, HDL-C TG, 
HRQOL, 
10-years risk assessment, 
disease knowledge & 
med. adherence  
L2&3 Statistical significant 
difference in all 
measures. 
CHEN et al. 
2016 (53) 
Taiwan 
3 100 (control 
=  50; 
intervention 
50) 
Diagnosed with type 
two diabetes with 
poor control  
6 months  Nantou City 
hospital  
Intervention group received 
pharmaceutical 
care including identification and 
resolution of drug-related 
problems and established a 
consultation procedure. 
HbA1c 
Hospitalizations were also 
monitored  
L1&2 Statistical significant 
difference in HbA1c.  
 
One person was 
hospitalized in the 
control group, none in 
the intervention group 
CHUNG et al 
2014  (54) 
Malaysia 
1 241 
(Control= 
121, 
Intervention
= 120) 
Diagnosed with type 
2 DM, taking at least 
one antidiabetic 
medication 
12 months Malaysian 
Teaching 
Hospital 
Patient education on diabetes, 
hypertension, hyperlipidemia 
and medication adherence. 
Taught how to use a pill box, 
blood glucose meter and how to 
record readings. Received 
monthly calls from pharmacist. 
Data collected at baseline and at 
4, 8 and 12 months. 
Fasting blood glucose 
(FBG), HbA1c.  
Medication adherence. 
L2&3 Statistical significant 
difference in HbA1c at 
month 4, 8 and 12 and 
on medication 
adherence. 
CLIFFORD et al. 
2005 (55) 
Australia 
3 180 (control 
= 88; 
intervention 
92) 
Diagnosed with type 
two diabetes. 
Enrolled in the 
Fremantle Diabetes 
study 
12 months Community 
based patients  
Counselling at 6 and 12 months 
in addition to 6 weekly telephone 
calls 
Diet, exercise and compliance 
was encouraged.  
Educational pamphlets were 
provided 
BMI, systolic and diastolic 
BP, fasting plasma 
glucose, HbA1c, serum 
lipid parameters and 
urinary albumin-to- 
creatinine ratio and 
exercise  
L2&3 Statistical significant 
difference in BMI, 
systolic and diastolic 
BP, fasting plasma 
glucose, and HbA1c 
DOUCHETTE et 
al. 2009 (56) 
USA 
2 66 (control = 
35; 
intervention
= 31) 
Diagnosed with type 
two diabetes who 
had completed two 
education sessions 
previously. 
12 months  Community 
based patients  
Four visits by a trained 
pharmacist at community 
pharmacy to assess any issues 
patient had.  
Diabetes clinic at the start and 
end of study. 
HbA1c, BP, LDL-
cholesterol, diet self-care 
activities,  diabetes self-
care activities, exercise 
self-care activities  
L2&3 Only self-care 
activities had a 
significant effect.  
ELNOUR et al. 
2008 (57) UAE 
3 165 patients 
(control= 66, 
intervention
= 99) 
Diagnosed with 
gestational diabetes, 
within first 20 weeks 
of gestation,  
UAE national. 
6 months Al-Ain 
Hospital, UAE 
Patients were educated on GDM 
& its management, insulin 
administration& storage, plasma 
glucose measurement. Provided 
with booklet. 
HRQOL (SF36), diabetes 
knowledge, insulin & 
plasma glucose 
monitoring, HbA1c, BP. 
Maternal & neonatal 
complications. 
L1&2 Significant differences 
in HRQOL scores, 
plasma glucose, 
insulin use, glucose 
monitoring & some 
maternal & neonatal 
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complications. 
JAMESON et al. 
2010 (58) USA 
3 103 
(controls= 
51; 
intervention 
= 52) 
Diagnosed with type 
two diabetes. 
12 months  Community 
based patients  
Patient intervention included 
regular care plus medication 
management, patient education, 
and disease control. 
6 office visits and 3 phone calls 
to patients  
HbA1c L2 Statistically significant 
difference overall  
JARAB et al. 
2012 (59) 
Jordan 
3 156 (control 
= 77; 
intervention 
79) 
Diagnosed with type 
two diabetes. 
6 months  Outpatient 
diabetes clinic 
Patients received face-to-face 
education and necessary 
lifestyle changes, followed by 8 
weekly telephone follow-up calls.  
HbA1c, BP, lipid values, 
self-reported medication 
adherence, and self-care 
activities 
L2&3 Statistically significant 
difference in all 
measures apart from 
BMI and HDL-
cholesterol and 
adherence. 
MAHWI et al.  
2013 (60) Iraq 
 
 
3 123 patients 
(control= 61, 
intervention
=62) 
Diagnosed with type 
2 diabetes mellitus  
3 months Diabetic 
centre in 
Sulaimani 
Intervention group received 
pharmaceutical care  
HbA1c, fasting plasma 
glucose. 
Drug therapy problems & 
med. compliance  
L2&3 Statistical significant 
difference in fasting 
plasma glucose and 
HbA1c. 
MCLEAN et al 
2008 (61) 
Canada 
3 211 patients 
(Control = 
109; 
Intervention 
= 102) 
Patients with 
diabetes with BP 
>130/80mmHg 
on 2 screening visits 
separated by 2 
weeks  
 
24 weeks  Community 
pharmacy 
patients 
The intervention was delivered 
by pharmacist-nurse teams 
at various pharmacy sites. 
Cardiovascular risk reduction 
counselling was provided 
The patient received a wallet 
card documenting their BP  
Intervention group patients were 
seen at 6-week intervals by the 
study nurse and pharmacist for 
counselling and measurement of 
BP. 
Primary outcome: Change 
in SBP 
Secondary outcomes: BP 
targets <130/80mmHg, 
change in antihypertensive 
drug therapy, the 
proportion prescribed an 
angiotensin-converting 
enzyme inhibitor or 
angiotensin receptor 
antagonist, and change in 
SBP in patients>160 mm 
Hg. 
L2 Statistical significant 
difference in systolic 
BP and also 
proportion of patients 
who achieved the goal 
BP of less than or 
equal to 130/80 mm 
Hg 
MOURAO et al. 
2013 (62) Brazil 
3 100 (control 
= 50; 
intervention 
50) 
Diagnosed with type 
two diabetes, using 
oral antidiabetic 
medications and 
presenting Hb 
A1c>7 
6 months Six primary 
health care 
units 
Designed a care plan for each 
patient focusing on patient 
education/pharmacotherapy 
changes 
HbA1c level, fasting blood 
glucose, TC*, LDLC, 
HDLC, DBP, SBP 
L2 Statistical significant 
improvement in all 
biochemical data & 
SBP (except BMI & 
DBP) 
OBRELI-NETO 
et al. 2011 (63) 
Brazil 
3 194 
Control=97 
Intervention
=97 
 
Aged ≥60 years, 
Diagnosed with 
diabetes or 
hypertension. 
36 months Primary public 
health care 
unit (PHCU) 
The interventions include 
assessment of non-adherence, 
discussions of the role of 
medication in their health, 
correct use of drugs and a visual 
aid. 
Group activities were carried out 
every 6 months. These 
discussed adherence, dangers 
of self-medication and correct 
storage of medicines. 
SBP,DBP, LDL--
cholesterol,HbA1c, fasting 
blood glucose, 
QALY 
L2&3 Statistical Significant 
difference in surrogate 
outcomes 
Cost effective 
ICER*/QALY 
ODEGARD et al 
2005 (64) USA 
3 77 (control – 
34; 
intervention 
Diagnosed with type 
two diabetes with 
HbA1c >9 and 
12 months  University of 
Washington 
Neighbourhoo
Diabetes care plan followed by 
weekly visits or telephone calls, 
which was reduced to less 
HbA1c, adherence  L2&3 No significant 
differences 
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= 43) taking >1 oral 
antidiabetic  
d Clinics frequent when needs were 
progressing.  
WISHAH et al. 
2014 (65) 
Jordan 
3 101 (control 
= 51; 
intervention 
50)  
Diagmosed with 
type two diabetes  
6 months  Jordan 
University 
hospital 
outpatient 
clinic  
Patient education about the 
condition and complications, 
lifestyle advice, medicines, 
adherence and written material. 
Follow-up phone calls to remind 
patients of adherence and of the 
appointments for follow-up visit.  
HbA1c, fasting blood 
glucose, patient 
knowledge 
L2&3 All measures show 
significant differences 
XIN et al. 2015 
(66) China 
3 240 (control 
= 120; 
intervention 
120) 
Diagnosed with type 
two diabetes, newly 
prescribed insulin 
therapy  
12 months  Tongde 
Hospital  
Patients received individualized 
education, educative group 
activities, and telephone 
counselling. Group activities 
were carried out every 6 months. 
These discussed adherence, 
dangers of self-medication and 
correct storage of medicines. 
HbA1c, hospitalization, 
measures of adherence  
L1, 2 &3 Significant differences 
in HbA1c and 
hospitalizations 
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Table 5. RCTs evaluating pharmaceutical care in depression (n=2) 181 
Reference  and 
country 
Jadad 
score 
Sample size  Study population Follow up 
period   
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcome Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
MARQUES et al 
2013 (67) Brazil 
3 48 patients 
(Control= 22, 
Intervention= 
26) 
Patients with 
depression  
3 months Outpatient 
clinic 
Pharmaceutical intervention 
according to the Dáder Method, 
receiving visits every 30 days, or 
more frequently if necessary. 
Oral and written information 
were given. 
Beck Depression 
Inventory and Beck 
Anxiety Inventory  
L2 Statistically significant 
difference in the Beck 
Depression Inventory 
score  and Beck 
Anxiety Inventory 
score  
RUBIO-VALERA 
et al 2013 (68) 
Spain 
3 151 patients 
(Control= 87, 
Intervention= 
64) 
Patients with 
depression 
6 months  4 Primary 
Care Health 
Centres 
Adherence, satisfaction with 
service, HRQOL and clinical 
severity. Follow-up visits to 
monitor progress,  
Outcome measurements 
included clinical severity of 
depression (PHQ-9), 
health-related quality of 
life (HRQOL) (Euroqol-5D) 
and satisfaction 
L2&3 Statistically significant 
difference in HRQOL 
  182 
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Table 6. RCTs evaluating pharmaceutical care in older adults (n=6) 183 
Reference  and 
country 
Jadad 
score 
Sample size  Study population Follow up 
period  
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcome Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
CROTTY et al. 
2004 (69) 
Australia 
3 110 patients 
(Control= 54, 
Intervention= 
56) 
Hospital patients 
awaiting discharge 
to a long term care 
facility 
8 weeks Hospital 
patients 
awaiting 
discharge to a 
long term care 
facility 
A medication review  
Within 10 to 14 days of the 
transfer. The transition 
pharmacist, patient, family 
physician, the community 
pharmacist, and a registered 
met between 14&28 days post 
transfer. Education concerning 
medication use and 
appropriateness was given. 
Hospital usage, 
Medication 
Appropriateness Index, 
adverse drug events, falls, 
worsening mobility, 
worsening behaviors, 
increased confusion, and 
worsening pain. 
L2 &3 Significant differences 
in hospital usage and 
worsening pain 
HOLLAND et al. 
2005 (70) UK 
3 829 patients 
(Control= 
414, 
Intervention= 
415) 
Home based 
medication review 
after discharge from 
acute or community 
hospitals 
6 months  Home based 
medication 
review after 
discharge from 
acute or 
community 
hospitals in 
UK 
Two home visits post discharge 
to educate patients and carers 
about their drugs, inform general 
practitioners of drug reactions or 
interactions. 
Total emergency 
readmissions.  Secondary 
outcomes included death 
and 
quality of life  
L1, 2&3 Significant differences 
in hospital 
readmissions and 
QOL scores 
LENAGHAN et 
al. 2007 (71) UK 
3 105 patients 
(Control= 49, 
Intervention= 
56) 
> 80 years of age, 
living at home, 
taking four or more 
medicines, and had 
at least one 
additional 
medicines-related 
risk factor. 
6 months Home-based 
medication 
review  
Two home visits for education  
of patient/carer about their 
medicines, pharmaceutical care 
issues were noted, assessed 
need for an adherence aid 
Hospital admissions, QOL 
scores & number of 
medication prescribed 
L1&3 Significant reduction in 
the mean number of 
medicines prescribed 
LENANDER et 
al 2014 (72) 
Sweden 
2 141 patients 
(Control= 66, 
Intervention= 
75) 
> 65 years with five 
or more different 
medications 
12 months  GP practice  A medication review was 
performed open 
for patients questions  
Drugs and dosages were 
evaluated and patients were 
asked about concordance. 
Concluding pharmaceutical 
advice was given to patients and 
entered into the computerized 
patient record. 
Follow up at 12 months  
Hospitalizations, self-rated 
health, drug related 
problems and number of 
drugs  
L1&3 Significant differences 
in drug related 
problems, in the 
number of medications  
OLESEN et al. 
2014 (73) 
Denmark 
 
 
3 517 patients 
(Control= 
264, 
Intervention= 
253) 
Aged ≥ 65 years, 
with a least 5 current 
prescription drugs 
taken without 
assistance.  
24 months Patients were 
visited by 
pharmacists at 
their homes.  
Medication review. 
Informed the patients about 
drugs, provided information 
leaflets & motivated adherence. 
Follow-up telephone call at 3, 6 
and 9 months,  
Primary outcomes 
Treatment adherence 
assessed by a pill-count. 
Secondary outcomes 
DRPs, hospitalization & 
mortality 
L1&3 No significant 
difference. 
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SPINEWINE et 
al. 2007 (74) 
Belgium 
3 172 patients 
(Control= 83, 
Intervention= 
89) 
Aged >70 with 
geriatric problems  
12 months  Acute Geriatric 
Evaluation 
and 
Management 
unit 
Pharmaceutical care was 
performed The appropriateness 
of treatment was analyzed, and 
a pharmaceutical care plan was 
prepared.  At discharge, the 
pharmacist provided written and 
oral information on treatment 
changes to the patient or 
caregiver, as well as written 
information to the general 
practitioner. 
Medication 
Appropriateness Index 
(MAI), Beers criteria, and 
Assessing Care of 
Vulnerable Elders 
(ACOVE) underuse criteria 
and mortality, 
readmission, and 
emergency visits. 
L1&2 Significant differences 
in the MAI and in the 
ACOVE underuse 
criteria  
 184 
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Table 7. RCTs evaluating pharmaceutical care in respiratory conditions (n=3) 186 
Reference  and 
country 
Jadad 
score 
Sample size  Study population Follow up 
period 
(months)  
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcome Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
ABDELHAMID 
et al. 2008 (75) 
Sudan 
3 78 Patients 
(Control=30, 
Intervention= 
48) 
Diagnosed with 
asthma  
6 months Shaab 
Teaching 
Hospital 
Drug therapy for asthma was 
reviewed; patients were 
educated about the disease, 
non-drug therapy measures, 
pharmacotherapy, self-
management & inhalation 
technique every two weeks.  
Frequency of acute 
attacks, nocturnal 
symptoms, using short 
acting inhaled β2-agonist, 
days of sickness per 
week. 
L1, 2 &3 Statistical significant 
difference in frequency 
of attacks, nocturnal 
symptoms and 
frequency of reliever 
use. Also significant 
difference in the days 
sick. Patient inhaler 
technique and 
knowledge also 
improved. 
TOMMELEIN et 
al. 2014 (76) 
Belgium 
3  692 patients 
(Control=346
, 
Intervention= 
346) 
 
 
 
Aged  ≥ 50 years 
COPD patients, 
Prescribed with 
COPD medications 
 
3 months 170 
community 
pharmacies 
Two session intervention one at 
the start and one at one month. 
Inhalation technique, med. 
adherence, hospitalization rate. 
Patients also given written 
information and demonstration 
units. 
Primary outcomes 
Inhalation technique, med. 
adherence. 
Secondary outcomes  
Dyspnea, hospitalization 
rate, health status & 
smoking behavior. 
L1&3 Statistical significant 
difference found in 
inhalation technique, 
adherence and 
hospitalization rates. 
WEI et al. 2014 
(77) China 
3 87 patients 
(Control= 45, 
Intervention= 
42) 
Stable COPD 
patients with a t 
least 2 consecutive 
visits to this hospital 
for COPD treatment 
 
12 months Medical 
University 
affiliated 
Hospital  
A comprehensive 
pharmaceutical care program 
composed of individualized 
patient education & a series of 
telephone counselling 5-6 
sessions. 
Primary outcomes 
Medication adherence by 
pill-count & questionnaire. 
Secondary outcomes 
Severe exacerbation rate 
& HRQOL. 
L1&3 Statistical significance 
in adherence, hospital 
admissions and 
symptoms and impact. 
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Table 8. RCTs other studies evaluating pharmaceutical care (n=4) 188 
Reference  
and country 
Jadad 
score 
Sample size 
(completed  
follow up) 
Study population Follow up 
period 
(months)  
Setting for 
study 
recruitment 
Study outline 
(Intervention provided) 
Outcome Measure 
 
 
Level of 
outcome 
measure 
(L) 
Effect of intervention 
BASHETI et 
al. 2016 (78) 
Jordan 
3 160 patients 
(Control=78, 
Intervention= 
82) 
>18 years, at least 
one long term 
condition and 
prescribed >3 
medications 
Average 3 
months  
Community 
pharmacy  
Baseline  MMR was conducted 
for all patients, 
recommendations regarding the 
identified TRPs were only 
submitted to the physicians of 
patients in the intervention 
group. Follow-up then occurred 
at the end of the study. 
Resolution of treatment 
related problems. 
Prescriber acceptance of 
the advice; effect of the 
intervention on certain 
clinical outcomes: blood 
glucose levels, BP, and 
triglyceride levels. 
L2 &3 Significant difference 
in the treatment 
related problems that 
were resolved, blood 
glucose, BP and TG 
levels 
LAI et al. 
2011 (79) 
Malaysia 
3 177 patients 
(Control=89, 
Intervention= 
88) 
Aged≥ 45 years 
Postmenopausal 
women diagnosed 
with osteoporosis, 
prescribed with 
once weekly 
alendronate or 
risedronate. 
12 months University 
Malaya 
Medical 
Centre 
(UMMC) 
Counselling on osteoporosis, 
risk factors, lifestyle 
modifications, and goals of 
therapy, side effects & the 
importance of adherence. 
Written information given. 
Monthly follow-up calls for the 
first 6 months, then 3 monthly 
thereafter.  
Medication adherence, 
BTMs and persistence 
  
L3 Significant higher 
adherence. 
 
No significant 
difference in 
persistence  
LOSADA-
CAMACHO 
et al. 2014 
(80) 
Colombia 
3 144 patients 
(Control=74, 
Intervention= 
70) 
Aged >18 years, 
diagnosed with 
epilepsy from over 
a year, receiving 
out-patient 
treatment with 
anti-consultants, 
experienced at 
least one seizure 
in last 3 years. 
6 months Fundacion 
Liga Central 
Contra La 
Epilepsia, 
sede Bogota. 
Applied a pharmaceutical care 
program consisting of 5 parts.  
Medication review follow up 
according to Dader’s method, 
Lecture in group education 
sessions, 
Treatment adherence, 
registration of seizures & 
possible triggers, 
TDM of anticonvulsants 
Primary outcomes: 
HRQOL measured by 
QOLIE-31(Quality of Life 
in epilepsy Inventory-31). 
Secondary outcomes: 
Frequency of crises, 
adverse reactions, 
depression & adherence 
L1&3 Statistical significant 
difference in HRQOL. 
 
 
 
 
 
 
 
WU et al 
2006 (81) 
Hong Kong 
3 442 patients 
(Control=223, 
Intervention= 
219) 
> 5 medications 
and two 
appointments to 
the clinic 
24 months  Specialist 
medical centre 
at hospital  
Intervention group received a 
10-15 minute telephone call from 
our pharmacist at the midpoint. 
The pharmacist asked about the 
patient’s treatment regimens; 
provided education and 
reminded patients of their next 
clinic appointment; and 
reinforced the importance of 
compliance  
The primary endpoint was  
death from any cause. 
Other endpoints included 
changes in the rate of 
admission to hospital. 
 
L1 Statistically significant 
change in deaths  
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Impact of pharmaceutical care in disease management  189 
Cardiovascular disorders (Table 3) 190 
Twenty-four RCTs evaluated the impact of pharmaceutical care on the patients with cardiovascular 191 
diseases, of which 20 showed statistically significant clinical outcomes (27, 28, 30, 31, 34, 35, 38-51). 192 
Four studies showed no differences in the clinical outcome measures (29, 33, 36, 37) .  193 
Table 3 illustrates the 24 RCTs that have been conducted on cardiovascular conditions. Included in this 194 
category are studies evaluating the effect of interventions on patients with cardiovascular diseases (e.g. 195 
heart failure (36, 42, 47) or coronary heart disease (28, 29, 33, 37, 40), in patients with high 196 
cardiovascular risk factors (27),  hypertension (30, 31, 34, 38, 41, 46, 48, 50, 51) or dyslipidemia (39, 43, 197 
44, 49) and in two studies patients with metabolic syndrome (35, 45). The four studies that did not show 198 
significant differences in hospitalizations or clinical outcomes were in cardiac heart failure patients (36) 199 
and three in those with coronary heart disease (29, 33, 37).  200 
To note, two studies included patients that had been diagnosed with diabetes and cardiovascular 201 
conditions; these studies were included and discussed in the diabetes section. 202 
Clinical outcomes measured included BP, cholesterol levels blood glucose and cardiovascular risk. 203 
Eleven studies found significant differences in diastolic and/or systolic BP readings after the intervention 204 
(27, 30, 34, 35, 38, 39, 41, 46, 48, 50, 51). One study specifically aimed to evaluate whether patients met 205 
a target BP (46). Two studies found no significant differences in BP; one study by Garcia and colleagues 206 
(33) and another by Sadiq et al (47).  207 
Cholesterol readings were compared in twelve RCTs (27, 29, 31, 33, 35, 38-40, 43-45, 49); these 208 
measures included total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-c), 209 
and/or high density lipoprotein cholesterol (HDL-c) levels. Statistically significant differences were seen in 210 
TC (27, 39, 43, 44, 49), TG (35, 39, 43, 49), LDL-c (39, 40, 49) and HDL-c (39). 211 
Blood glucose was measured in two of the studies, but neither reported significant differences (33, 35).  212 
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Cardiovascular risk was calculated and compared in two studies. One study showed a significant 213 
reduction in CV risk after the intervention (31), but the other study showed no differences (29).  214 
Hospitalization rates were recorded Murray and colleagues, who found statistically significant differences 215 
after a pharmacist intervention in patients with low incomes and heart failure, however this difference 216 
dissipated after the intervention stopped (42) Furthermore, Holland et al. reported no significant 217 
differences in patients with cardiac heart failure after pharmacist intervention post-discharge from 218 
hospital. Unplanned health care utilization was found to be statistically significant in patients 219 
with low health literacy in the study by Bell et al. (28).  220 
Another study in patients with cardiac heart failure used exercise tolerance (2-minute walk), and 221 
forced vital capacity in order to evaluate the intervention, in addition to the measures described 222 
above. Statistical significant differences were found in both measures (47). 223 
Lalonde and colleagues’ RCT included patients who had been prescribed warfarin. They 224 
evaluated whether there were changes in INR control, complications and use of health care services, 225 
and found no differences after intervention by a pharmacist anticoagulation service (37). 226 
Diabetes mellitus (Table 4) 227 
Fifteen of the RCTs assessed the effect of pharmaceutical care intervention on various outcomes of the 228 
patients diagnosed with diabetes mellitus (Table 4). The majority of these involved the patients with Type 229 
2 diabetes mellitus (52-56, 58-60, 62, 64-66), one study included both Type 1 and Type 2 patients (61) 230 
and one study was unclear regarding the type of  patient that was included. One RCT involved the 231 
gestational diabetes mellitus patients (57).  232 
Ten studies found the significant reductions in HbA1c levels in the intervention group (52-55, 57, 59, 60, 233 
62, 63, 65), a further three studies measured HbA1c and found no significant differences (56, 57, 64). 234 
Nine RCTs measured the fasting plasma glucose level and significant reduction was observed in the 235 
pharmaceutical care group (52, 53, 55, 57, 59, 60, 62, 63, 65), compared with only one that did not find 236 
differences in fasting plasma blood glucose (54). Statistical significant decrease was found in total 237 
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cholesterol, LDL-cholesterol and/or systolic BP (52, 55, 59, 61-63, 82-84) and an increase in HDL-238 
cholesterol (52, 62). One RCT also recorded improvements in some maternal and neonatal complications 239 
(57).   240 
Hospitalizations and unexpected medical usage was recorded by a number of studies, but only reached 241 
statistical significance after a pharmaceutical care intervention in one study (66). 242 
Respiratory conditions (Table 5) 243 
Three studies evaluated the impact of pharmaceutical care and medicines management on the 244 
respiratory disorders patients including asthma and chronic obstructive pulmonary diseases (COPD) 245 
(Table 5). Two of these solely involved the COPD (76, 77) and one patients with asthma (75).  246 
Statistical significant differences were found in symptoms of the conditions i.e. frequency of attacks, 247 
nocturnal symptoms and frequency of reliever use in asthmatics (75) and exacerbations in COPD (77). In 248 
addition hospitalization rates were also statistically significant after intervention with pharmaceutical care 249 
(76, 77).   250 
Depression (Table 6) 251 
Two RCTs included in this review focused on pharmaceutical care interventions in depression. Clinical 252 
outcomes measuring clinical severity in the intervention groups led to mixed results. One study found a 253 
significant difference (67)  in clinical measures whereas the other did not (68). The latter study did lead to 254 
significant changes in HRQOL but not clinical severity. 255 
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Older adults (Table 7) 256 
Six studies evaluated pharmaceutical care interventions in older adults, with mixed results (Table 6); four 257 
studies showed statistical significance in clinical outcomes or hospitalizations (69-71, 74), whereas two 258 
showed no difference (72, 73).  Hospitalization rates were reported in all of the six RCTs, with two studies 259 
finding differences after intervention of pharmaceutical care (69, 70). One study reported significant 260 
differences in worsening of pain (69) and three studies reported improvements in appropriateness (74) or 261 
number (71, 72) of medicine prescribed. 262 
Other studies included (Table 8) 263 
Multiple medications  264 
Two RCTs involved the implementation of interventions for patients who were on multiple medications; 265 
one study patients included in the RCT needed to be taking a minimum of three medicines (78) and the 266 
second study the patients needed to be taking five or more medications (81). The study by Basheti and 267 
colleagues (2016) was community pharmacy based using a medication management review and the 268 
primary outcome was resolution of drug related problems, acceptance of advice by prescribers plus 269 
clinical outcomes of blood glucose levels, BP and triglyceride levels. Significant differences were seen in 270 
drug related problems resolved and all clinical outcomes (78).  The second study in this category was set 271 
in a specialist medical center and the primary endpoint was death of any cause and rate of 272 
hospitalizations. Differences were found in number of deaths (81).  273 
Epilepsy 274 
Losada- Camacho and colleagues (2014) evaluated the impact of pharmaceutical care program on 275 
women with epilepsy (80) (Table 8). The primary outcome was health related quality of life (HRQOL) 276 
measured by Quality of Life in Epilepsy Inventory-31 (QOLIE-31) and the secondary outcomes included 277 
the changes in frequency of seizures, depression measured by using the questionnaire of the Center for 278 
Epidemiologic Studies Depression Scale (CES-D), adverse drug reactions by Liverpool Adverse Event 279 
Profile (Liverpool AEP) and adherence by using Haynes-Sackett test and Moriski-Green test. Significant 280 
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differences were seen in QOLIE-31 scores. No significant differences were seen in the frequency of 281 
seizures. 282 
Osteoporosis 283 
A RCT assessed the effects of pharmaceutical care on adherence and persistence of bisphosphonate in 284 
postmenopausal osteoporotic women (79). Primary outcome measures were medication adherence, bone 285 
turnover markers (BTMs) and persistence (Table 8).  Two BTMs serum C-terminal cross-linking 286 
telopeptide of type I collagen (CTX-I) and serum osteocalcin (OC) were assessed. No significant 287 
reduction was found in in CTX-1 and OC between the two groups (79).     288 
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Discussion  289 
This systematic review aimed to evaluate the effectiveness of pharmaceutical care, based on RCTs that 290 
have been published between 2004 and January 2017. There have been a steady number of studies 291 
emerging over the past decade evaluating pharmaceutical care, leading to a high number of studies that 292 
were included in this review. Our findings suggest that pharmaceutical care, in the majority of cases, is 293 
effective in either decreasing hospitalizations or improving surrogate clinical outcomes particular to the 294 
presenting condition.  The included studies are all RCTs, which are considered the gold standard of 295 
clinical effectiveness if the methodology is properly executed (19), however RCTs in pharmaceutical care 296 
are often challenging to conduct and this could be a reason for a bias toward studying certain conditions 297 
and not others – for example there are 24 studies for cardiovascular conditions versus 3 for respiratory 298 
conditions. The spectrum of papers include a wide a variety of interventions, outcome measures and 299 
follow-up frequency and schedules, often making it challenging for researchers and healthcare 300 
professionals to directly compare and evaluate why certain studies have not found significant results.  301 
In addition to the current literature, our review has identified that there is strong evidence to support 302 
pharmaceutical care in long term conditions affecting patients with hypertension and dyslipidemia. 303 
Surrogate clinical outcomes of BP and cholesterol levels have shown to be systematically improved in the 304 
majority of studies; interestingly despite these two biomarkers being integral to the calculation of 5-year 305 
cardiovascular risk, only one study (out of two) showed significant improvements in 5-year cardiovascular 306 
risk. A systematic review published by Aguiar and colleagues (2012) focused on pharmaceutical care in 307 
hypertensive patients and found similar results to the present study (19). Systolic BP was the most 308 
positively impacted clinical outcome by the pharmaceutical intervention. The authors of the 2012 review 309 
described the need to improve research design, as there were limitations in hardiness (19). In 2011 310 
Morgado and colleagues conducted a systematic review and meta-analysis of pharmacist interventions to 311 
enhance BP therapy; results of this review showed that pharmacist interventions can significantly improve 312 
medication adherence, systolic BP, diastolic BP, and BP control in patients with essential hypertension 313 
(20). However in this review, one important limitation noted by the authors were the databases available 314 
for the systematic review, potentially therefore missing potential eligible studies.   315 
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In this review, the outcomes in relation to CHF and CHD were mixed. In is not as clear whether 316 
pharmacist intervention via pharmaceutical care is as effective; this may be due to fewer RCTs available 317 
in these conditions. In 2008 Koshman et al. published a systematic review in patients with CHF, including 318 
studies prior to 2007. Despite inclusion of 12 RCTs, outcomes were similar to our current review; mixed 319 
results for HF hospitalizations (3 of 11 studies finding significant differences) and mortality rates showing 320 
no significant differences. Overall, when the authors of this study pooled responses for outcomes, 321 
benefits were seen in pharmacist intervention (85). Further studies need to be conducted to clarify the 322 
effectiveness of pharmacists in these conditions. 323 
Pharmacists play a significant role in the provision of a pharmaceutical care services in diabetes mellitus. 324 
Our findings show strong evidence that pharmaceutical care interventions have significant positive effects 325 
in the reduction of HbA1c level in patients with diabetes. This finding is similar to other studies that have 326 
focused on diabetes, for example Fornos et al. (86) and Balaiah et al. (87), where glycemic control was  327 
found to be significantly improved as a result of pharmaceutical care interventions; ultimately lowering of 328 
HbA1c being a predictor of improved therapeutic outcomes of patients (88).   329 
A previous Cochrane review did not show that pharmaceutical care is effective in older adults (89), this 330 
current review reported mixed outcomes for hospitalizations and included measures of appropriateness of 331 
medications and health related quality of life. Our study focused on surrogate clinical outcomes and 332 
hospitalizations and included six RCTs, with an overall unclear conclusion regarding the benefit of 333 
pharmaceutical care intervention in this population. Four studies showed improvements after 334 
pharmaceutical care interventions, whilst two did not. This is also in line with a previous review by Holland 335 
and colleagues who concluded that pharmaceutical care does not impact on hospitalizations and 336 
mortality, however the authors do suggest that interventions could potentially improve knowledge 337 
and adherence (90). 338 
The three respiratory studies were included in this review, all showed significant changes after a 339 
pharmaceutical care intervention.  Health resource utilization (76, 77), symptoms (77) and inhalation 340 
techniques (76) were found to be improved in COPD patients. Similar results were seen in asthmatic 341 
patients, with improvements in symptoms, frequency of attached and reliever use (75).  342 
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No significant differences in hospitalizations or clinical surrogate outcomes were seen in patients with 343 
epilepsy, osteoporosis and depression. This could be due to the limited studies that have been 344 
conducted, and in the  case of the study by Losada-Camacho et al. a relatively low number of patients 345 
returned their seizure diary (80).  346 
 347 
Like previous literature, this study highlights the potential that pharmaceutical care has in a number of 348 
conditions, but goes further to identify some conditions that pharmaceutical care may not lead to changes 349 
in clinical outcomes. These non-significant results are challenging to interpret, they could be due to a 350 
myriad of factors including shorter follow up period insufficient for the examination of intervention effects 351 
and measurement of endpoints, the training of the pharmacists involved, the frequency of monitoring in 352 
the staff and the nature of those follow-up sessions.  353 
This review also highlights the need for consistency across studies in the future in terms of the clinical 354 
outcomes measured. Despite grouping the studies in this review into condition groups, within each 355 
condition there was a wide range of outcomes reported. This makes it challenging to be able to conduct a 356 
meta-analysis. Only the cardiovascular and diabetes section had a sufficient number of studies to be able 357 
to further assess a subset of the condition, for example blood pressure. However, if a meta-analysis were 358 
to be conducted on such a specific subset, it may most appropriate to include all RCTs that have been 359 
conducted on the topic, with no date limitation. This is out of the scope of this potential review, but could 360 
be the topic of future research. If there could be a consensus of future research to all collect data on a 361 
specific outcome, a meta-analysis could be conducted to look at pharmaceutical care overall. 362 
Currently there is a gap in current knowledge regarding the long term effects of pharmaceutical care 363 
interventions. Cooper and colleagues reported that patients show improvements in the first six months of 364 
interventions due to the psychological effects of being monitored, and this often drops off thereafter (91). 365 
The most frequently used follow up time in our review was six months, and one study did note that the 366 
beneficial effects seen dissipated when the intervention ceased (42). Future intervention studies with 367 
pharmaceutical care should bear this in mind. One of the studies in our review did have a sham 368 
intervention condition, and this study did find significant differences after pharmaceutical care (30).  369 
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Possibly future studies should aim to have a sham arm to the trial, therefore the pharmaceutical care 370 
aspect of the intervention can be differentiated in the methodology (19). In addition long term 371 
consequences of these interventions should be examined.  372 
  373 
The present study has certain limitations. The study is limited to the English language literature and 374 
studies in other languages were not included. Only original research RCTs are included in the review; 375 
secondary studies were excluded. This study also included the specific outcomes of hospitalizations, 376 
mortality and surrogate clinical outcomes, therefore not incorporating HRQOL score, patient satisfaction 377 
or adherence scores, future studies could focus on these aspects to evaluate the full spectrum of 378 
pharmaceutical care effects on patients.  379 
Conclusion  380 
RCTs conducted to evaluate pharmaceutical care appear to be effective in improving patient short-term 381 
outcomes for a number of conditions including diabetes and cardiovascular conditions, however, other 382 
conditions such as depression are less well researched. Future research should attempt to evaluate 383 
whether these effects persist and the long-term clinical outcomes. 384 
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